We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

112 hedge funds and large institutions have $215M invested in Arbutus Biopharma in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 34 increasing their positions, 29 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 7

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

49% more capital invested

Capital invested by funds: $144M → $215M (+$71M)

18% more call options, than puts

Call options by funds: $4.66M | Put options by funds: $3.94M

17% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 29

13% more funds holding

Funds holding: 99 → 112 (+13)

8.96% more ownership

Funds ownership: 42.28% → 51.24% (+9%)

Holders
112
Holders Change
+13
Holders Change %
+13.13%
% of All Funds
1.63%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
21
Increased
34
Reduced
29
Closed
7
Calls
$4.66M
Puts
$3.94M
Net Calls
+$718K
Net Calls Change
+$63K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$17.1M
2
WCM
Whitefort Capital Management
New York
+$2.55M
3
TSC
Two Seas Capital
New York
+$1.49M
4
CC
Centiva Capital
New York
+$684K
5
State Street
State Street
Massachusetts
+$461K

Top Sellers

1
JFG
Jefferies Financial Group
New York
-$537K
2
FCM
FourWorld Capital Management
New York
-$492K
3
KC
Kepos Capital
New York
-$316K
4
Citigroup
Citigroup
New York
-$230K
5
Ameriprise
Ameriprise
Minnesota
-$199K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$34.9M +$17.1M +8,707,094 +165%
WCM
2
Whitefort Capital Management
New York
$33M +$2.55M +1,301,585 +11%
BlackRock
3
BlackRock
New York
$26M +$227K +116,159 +1%
TSC
4
Two Seas Capital
New York
$22.6M +$1.49M +761,109 +9%
Vanguard Group
5
Vanguard Group
Pennsylvania
$15M +$80K +40,861 +0.7%
WP
6
Woodline Partners
California
$11.8M – – –
Hudson Bay Capital Management
7
Hudson Bay Capital Management
Connecticut
$10.3M -$19.6K -10,000 -0.2%
ACM
8
ADAR1 Capital Management
Texas
$8.67M +$6.79M +3,468,824 New
Geode Capital Management
9
Geode Capital Management
Massachusetts
$7.04M +$236K +120,611 +4%
State Street
10
State Street
Massachusetts
$5.99M +$461K +235,359 +11%
Citadel Advisors
11
Citadel Advisors
Florida
$4.83M -$165K -84,219 -4%
Millennium Management
12
Millennium Management
New York
$3.84M -$89.4K -45,648 -3%
CC
13
Centiva Capital
New York
$3.55M +$684K +349,015 +33%
Osaic Holdings
14
Osaic Holdings
Arizona
$3.42M -$979 -500 -0%
FCM
15
FourWorld Capital Management
New York
$2.73M -$492K -251,056 -19%
Northern Trust
16
Northern Trust
Illinois
$2.67M +$5.58K +2,849 +0.3%
Assenagon Asset Management
17
Assenagon Asset Management
Luxembourg
$2.04M – – –
Bank of New York Mellon
18
Bank of New York Mellon
New York
$1.14M +$10.5K +5,361 +1%
BFM
19
Boothbay Fund Management
New York
$1.13M -$74.6K -38,093 -8%
KCM
20
Kennedy Capital Management
Missouri
$968K -$11K -5,602 -1%
Bank of Montreal
21
Bank of Montreal
Ontario, Canada
$895K +$62.8K +32,081 +10%
Charles Schwab
22
Charles Schwab
California
$873K – – –
N
23
Nuveen
North Carolina
$735K +$4.18K +2,134 +0.7%
BNP Paribas Financial Markets
24
BNP Paribas Financial Markets
France
$730K +$97.4K +49,745 +21%
LWA
25
Ledgewood Wealth Advisors
New Hampshire
$696K +$545K +278,436 New
1
2 3 4 5

ABUS Hedge Fund Activity: Q4 2023 in Review

112 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2023, worth a combined $215M — up 49% from $144M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ABUS positions and 7 closed out — a net gain of 14 holders — while 34 added to existing stakes and 29 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $17.1M. The largest seller was Jefferies Financial Group, exiting entirely with an estimated $537K sold.

  • 112 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2023, up from 99 in Q3 2023.
  • Funds reported $215M of Arbutus Biopharma stock for Q4 2023, up 49% quarter-over-quarter.
  • 21 funds opened new Arbutus Biopharma positions in Q4 2023 and 7 closed out, a net change of +14 holders.
  • The largest Arbutus Biopharma buyer in Q4 2023 was Morgan Stanley, an estimated $17.1M added.
  • The largest Arbutus Biopharma seller in Q4 2023 was Jefferies Financial Group, an estimated $537K sold.

Based on aggregated 13F filings for Q4 2023.